Jan 18 2010
ChromoCure, Inc. (PINKSHEETS: KKUR) is pleased to
announce the publication of the Cervical Cancer Study, PRE-CLINICAL SYSTEM
TESTING AND PERFORMANCE ASSESSMENT, conducted in conjunction with a major
international Cancer Clinic. The study analyzed samples supplied by the
Cancer Clinic with its Proprietary Chromosomal Scanner Technology (full
text can be found @ www.ChromoCure.com/library). The study demonstrated
not only the correctness of the company's cancer detection approach but
also the accuracy of the scan itself. The scanner performed perfectly with
flawless detection results.
This exploratory study, using sub-optimal clinical samples, demonstrated:
1) the efficacy of using an automated system to detect aneuploid cells
in real-world specimens;
2) the detection of aneuploid cells is diagnostic of cervical lesions; and
3) the scanner's superb performance at not only detecting cancer but
achieving the near theoretical maximum agreement with error containing
data.
Additionally, the Company's technology was reaffirmed and further confirmed
by recent Mayo Clinic researchers. Their findings, which appear in the
December 2009 issue of the journal Cancer Cell along with an independent
commentary on the discovery, end a major controversy in the field of cancer
research as to whether aneuploidy is a cause or a consequence of cancer and
further proves the aneuploidy basis of cancer. Given the new credibility
of the chromosomal theory of cancer provided by the Mayo Clinic, the
results of this performance study become immediately significant and
relevant and further underscore both the correctness of the chromosomal
basis of cancer as well as the performance of the company's technology.
These recent publications enhance the company's international activities to
promote its cancer detection system and related technology through its
ChromoCure Cancer Research & Diagnosis Centers program. The research
further confirms the chromosomal theory of cancer and immediately
establishes the company's technology in the forefront of both cancer
detection and research.
ChromoCure's proprietary CS200 Chromosomal Scanner system and related
technology is specifically designed to target the unique chromosomal
characteristics demonstrated in the Mayo Clinic research. Detecting the
unique chromosomal signature of cancer yields an effectively 100% accurate
method of detecting all forms of cancer at all stages.
The company's systems detect the single characteristic found in 100% of all
cancers at all stages, and never found in normal cells. The company
therefore believes its technology detects cancer with an effective 100%
specificity and effective 100% accuracy. The Company's technology also
objectively measures, with high precision, the level of cancer present and
its stage of progression.
SOURCE: ChromoCure, Inc.